FDA Approves IMCIVREE for Acquired Hypothalamic Obesity, First & Only Therapy for Rare Disease
RYTM sits 97% above its 52-week low of $45.905.
Summary
Rhythm Pharmaceuticals announced FDA approval for an expanded indication of IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity (HO), making it the first and only approved therapy for this rare condition. This approval, supported by positive Phase 3 TRANSCEND trial data showing a significant -18.4% placebo-adjusted BMI reduction, opens a new market opportunity for the company, addressing an estimated 10,000 patients in the U.S. This positive regulatory development provides a significant catalyst, especially following the recent news of setmelanotide failing its primary endpoints in the EMANATE trial for a different indication. The expanded label for IMCIVREE is expected to drive revenue growth and reinforces the company's position in rare neuroendocrine diseases. Traders will now focus on the commercial launch and patient uptake for this new indication.
At the time of this announcement, RYTM was trading at $90.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $45.91 to $122.20. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.